INTRODUCTION
Treatment of progressive lung disease in cystic fibrosis (CF) has improved greatly over the last 30 years, leading to improvement in survival well into adult lifel. This has led to clinicians paying increasing attention to both treating and delaying progression of disease in other affected organs. A recent epidemiological study2 reported that the clinical prevalence of cystic fibrosis-related liver disease is relatively uncommon in young children but rises to a peak in adolescence.
The pathogenesis of liver involvement in CF remains unclear, partly because there are still insufficient long-term data on large numbers of patients. The end point seen at post-mortem is focal biliary cirrhosis which is the typical histological lesion found in those CF patients with liver disease and is characterized by portal ducts containing an inspissated granular eosinophilic material, bile duct proliferation, chronic inflammatory infiltration and some fibrosis3. This may progress to multilobular cirrhosis which has a reported incidence of up to 4% in one clinic4. Periportal changes were also seen with excessive mucus in the biliary tract3. These observations led to the suggestion that the development of focal biliary cirrhosis may be related to mucus obstruction in the intrahepatic ducts3 but this remains uncertain. Recently, the cystic fibrosis transmembrane regulator (CFTR) was found to be located at or near the apical membrane of the intrahepatic bile duct epithelium5. This observation has been followed by a hypothesis that a primary defect in biliary chloride transport may cause abnormal bile flow and thus contribute to the pathophysiology. In CF the faecal losses of bile acids and taurine (a bile acid conjugate) are high, resulting in a greater proportion of glycine-conjugated bile acids which are potentially more hepatotoxic than taurine-conjugated bile acids and may contribute to the bile duct injury6. It is likely that these mechanisms may lead eventually to intrahepatic bile duct irregularities seen at endoscopic retrograde cholangiography7 and to the observed post-mortem findings of CF liver disease. No association between genotype and development of liver disease has been found so far. A recent study analysing the risk factors for the development of liver disease associated with CF showed no difference in allele frequencies between those with and those without liver involvement8.
Early detection and assessment of progression of CFliver disease can be difficult. By the time clinical liver disease is evident, usually portal hypertension and cirrhosis have already developed. At this stage, the only potentially curative treatment may be liver transplantation9. Biochemical markers of liver function may not be useful in the assessment of liver involvement because any hepatocyte dysfunction is due to the secondary effect of the primary intrahepatic ductal lesion and the level of abnormality does not always correlate with clinical evidence of liver disease6. Abnormalities of these tests may also be due to an effect other than CF liver disease such as an adverse effect of a drug treatment or bacterial infectionl. Ultrasound appearances of liver size and irregular texture, as well as Doppler studies of altered direction and velocity of portal vein flow can be used to assess the presence and progression of liver disease or portal hypertension1 1. A recent study has suggested that measuring biliary excretion of disopropylphenyl-carboxymethyl iminodiacetic acid (DISIDA) by radioisotope scanning with hepatic scintigraphy may be useful in assessing early liver involvement12.
Recent developments in therapy have been directed towards attempting to improve biliary secretion and bile acid composition. Ursodeoxycholic acid (UDCA) is a naturally occurring hydrophilic bile acid which constitutes less than 4% of the total bile acid pool. In 1990, Erlinger et al. 13 showed that UDCA improves bile acid flow by inducing an increased bicarbonate-rich bile flow. Hydrophilic UDCA is less hepatotoxic than primary bile acids10.
Initially UDCA was used to dissolve gallstones but more recently has been used as a possible treatment for other adult chronic cholestatic liver diseases such as primary biliary cirrhosis14 and primary sclerosing cholangitis1 .
Following these trials, UDCA was found to improve liver function tests in CF liver disease16 and has since been used in the treatment of and hopefully in the prevention of progressive liver disease in CF in recent years.
A dose response study suggested that a dose of 20 mg/ kg/day or greater was needed to optimize biliary UDCA enrichment and biochemical improvement.'7 The recommended dose of oral UDCA is taken twice or three times a day18 initially for months but possibly indefinitely. Diarrhoea as a side effect has been reported rarely18. In the UK, the cost of six months' (24 weeks) treatment with UDCA for a 10 year old child, weighing 30kg at a dose of 20 mg/kg/day is £212.
Randomized controlled trials (RCTs) are used to provide an unbiased assessment of effectiveness of new treatments, or as in the case of UDCA, existing treatments for new indications. However, because small sample sizes are often used, they may not provide conclusive results. The aim of The Cochrane Collaboration which was established in 1993, is to prepare, maintain and disseminate systematic up-to-date reviews of RCTs of health care19 and then to make these readily accessible using various electronic media through The Cochrane Database of Systematic Reviews within The Cochrane Library20. The purpose of systematic reviews is to demonstrate evidence of benefit or harm from interventions using existing evidence but also to indicate areas where further research is needed. These reviews should be kept up-to-date as new evidence becomes available. Reviewers are members of Collaborative Review groups working on reviews covering a particular topic. The Cochrane CF group was registered in September 1995. So far, a register of RCTs in CF has been established, four reviews are in progress and four other titles have been registered. The recent improved prognosis for CF patients in both morbidity and mortality has been associated with an increased range of treatments. It is most important that these are supported by good evidence of their effectiveness. UDCA, increasingly prescribed to CF patients for longterm use, is a good example. We now report a systematic review of RCTs using UDCA. We aim to assess the evidence for its effectiveness and in particular to consider its effect on long-term outcome measures. Although sources of evidence other than RCTs may be available, these will not be considered here.
METHODS
A protocol was drawn up and peer-reviewed.
Inclusion criteria
We aimed to identify all RCTs where UDCA had been compared to placebo or existing conventional therapy, in patients with CF. Criteria for inclusion in this review were:
1. Children and adults with CF, diagnosed on clinical ages, all degrees of liver involvement and all degrees of severity of CF were induded. 2. Any dose of UDCA administered orally, given for at least three months. 3. Randomized controlled trials or trials where pseudorandomized methods had been used, such as alternation or case-record number.
We intended to examine outcome measures at 3, 6, 12 months and annually thereafter ( Table 1 ). The inclusion criteria and outcome measures were determined prior to reading any of the identified RCTs to avoid bias. The outcome measures chosen were those which would be likely to be clinically relevant and important to patients. The protocol was read by the mother of a child with CF and also an adult CF patient to ensure that all possible outcome measures relevant to patients were included.
Search strategy for identification of studies
The Cochrane CF Group has recently established a specialist register of RCTs in CF21. References to RCTs were identified through detailed computerized searches of Medline and Embase. The search strategy for Medline was developed using methodology described by The Cochrane Collaboration22 together with subject terms for cystic fibrosis (Appendix 1). Unpublished work was identified from searching abstract books of the conference proceedings of The International CF conference, the European CF conference and the North American CF conference. Additional references were identified from citations in review articles. The RCTs on the register were coded according to intervention and therefore references to Selection of trials and data extraction The identified reports were assessed independently by two of us (KC and RS). Those RCTs which met the criteria were selected for inclusion in the review. Attempts to extract data from each RCT from text, tables and figures were made. Where sufficient data were not available in the published reports of the abstract of the conference proceedings, attempts to contact the first and last authors were made. We intended to record data on the number of patients with each outcome event, by allocated group, irrespective of compliance and whether or not the patient was later thought to be eligible or otherwise excluded from treatment or follow-up. This approach would allow an intention-to-treat analysis.
Methodological quality Methodological quality was assessed using a method described by Schulz23. The following dimensions of methodological quality: allocation concealment and generation of the randomization sequence were categorized as adequate, unclear or inadequate. Intention-to-treat analysis was categorized as adequate, unclear or exclusions. RCTs were categorized according to whether double-blinding had been reported or not.
RESULTS
Ten references were identified using the search strategy described. There were four references to one RCT, one from a citation24, two from abstract books25'26 and one sent by a pharmaceutical company27, two references to another study, one from Medline17 and another from an abstract book28. Of the remaining four references, two were from abstract books29'30, one from Medline3l and one from a citation32. The two studies which were excluded at this stage were a dose-response study17 in which there was no comparison with placebo or conventional treatment and one which was a multi-period, multi-treatment, crossover study but which had not been randomized30. Of the four RCTs identified, three met the inclusion criteria27'31 ,32. A fourth RCT was available only as an unpublished report29 with insufficient data on the lengt of time which UDCA had been prescribed and with only a six week follow-up period. We presumed that this was an interim report of preliminary results presented at a conference but we have been unable to identify a full publication or to obtain further details from the authors. Details of this RCT have been included in Tables 2 and 3 but have not been formally included in this review.
Methodological quality of each RCT was variable ( Table 2 ). The characteristics of the RCTs are outlined in Table 3 . There was considerable clinical heterogeneity between patients entered into these RCTs. In one RCT31, only 10/51 participants had liver disease whilst in another32, 11/12 had advanced liver disease (as determined by the presence of portal hypertension and/or histological features of fibrosis or cirrhosis).
Nutritional indices were one of only two predefined outcomes reported. Weight gain was reported in only one of the RCTs (Tables 3 and 4 )32. However, measures of weight before and after six months' treatment were reported in another RCT31. Skinfold thickness was reported in two RCTs3l,32. The results are summarized in Table 4 . Body mass percentile, which also takes into account the population mean weight and height rather than body mass index (weight in kg/height2 in metres) was reported in one study31.
We wished to examine the effect of UDCA on abnormal liver biochemistry by comparing the numbers of patients in both groups whose hepatocellular enzymes normalized to within the normal range of the method stated, at various time points. This was not reported as an outcome measure in any of the four RCTs but serving as a proxy for this, improvement in abnormalities of hepatocellular enzymes was measured in all four RCTs. However, raw data was available from one of the RCTs32 (O'Brien S; personal communication) to enable us to examine this outcome ( Table 5 ). The development of portal hypertension or its complications was not reported as an outcome measure in any of the four RCTs. However, portal hypertension did not develop in any of the patients in the two six month follow-up RCTs31'32 (O'Brien S, Merli M; personal communication). Reduction of an abnormally large liver, documented by ultrasound was not reported in any of the four RCTs. Improvement of biliary excretion, documented by isotope scanning was performed in one study32. The time in minutes from injection of the isotope to maximal hepatic activity and the percentage clearance of isotope from the liver and biliary tree at 45 and 60 minutes compared with maximal activity were measured. No significant changes in biliary excretion occurred after treatment with UDCA. Although need for liver transplantation was not used as an outcome measure, one study reported that one patient, who initially had multilobular cirrhosis and oesophageal varices and was allocated treatment with UDCA, was subsequently withdrawn due to further deterioration of liver function and proceeded to liver transplantation27. None of the patients in the two six- We stated the intention to use data on all randomized participants. However intention-to-treat data were present in only two of the RCTs27'32. In one study31, although withdrawals were mentioned, they were not included in the analysis and in the other29 it was unclear whether an intention-to-treat analysis had been performed.
The data presented in the crossover RCT appeared to be combined from both treatment periods31. Although we had not specifically excluded crossover studies, we were concerned about the use of a crossover design. This was because there may be a carry-over effect of UDCA into the control arm, although the authors attempted to overcome this by using a one month washout period. However, we only considered it appropriate to compare the first six months of the study, i.e. UDCA versus placebo before the patients crossed over. These separate data were not available in the published report and we have not been able to obtain it from the authors. The addition of taurine to this RCT and one other study further complicated their design. In the crossover study31 the patients were randomized to receive UDCA alone or with taurine and then each treatment group was compared with a placebo period. The sequence of treatment/placebo was then randomized in a crossover design. In the other27, a factorial parallel design was employed; patients were randomized to receive UDCA or placebo and then each group was further randomized to receive either taurine or a second placebo. In effect, four parallel groups were studied. Taurine may have an unknown effect on liver involvement, whilst UDCA is known to cause taurine depletion10, but their combined effect on liver function is not known. These possible interactions caused difficulties when we considered combining the data and, in the case of the crossover study we would have only been able to use the data from the first six months of the UDCA/placebo group and could not include the UDCA plus taurine group. Another issue of the crossover RCT was that although weight, height and body mass percentile were measured, we had concerns about this type of trial design because we would expect there to be a period effect on variables such as weight and height which would require more subtle analysis. We have received considerable help from a number of the authors of the RCTs but due to the lack of data on predefined outcomes, the differences in length of follow-up and the above complications in study design, we have been unable to perform a formal meta-analysis.
DISCUSSION
This first systematic review on the effectiveness of UDCA in CF highlights the paucity of RCTs specifically investigating this issue in CF. Disappointingly, these RCTs have not adequately examined our predefined outcome measures but provide important preliminary information which requires further evaluation. The data in these RCTs provide some evidence that UDCA improves liver function in CF but have not examined its effectiveness of UDCA in the prevention of CF liver disease nor in the reversibility or delayed progression of early or advanced liver disease. There was considerable variation in the outcome measures examined in the four RCTs and in the time-points at which they were measured.
Due to the lack of data on clinically relevant endpoints we were unable to perform a quantitative meta-analysis, but this systematic review provides an important summary of the information currently available from RCTs on the use of UDCA. This information may be used to inform the design of subsequent RCTs. In defining outcome measures we paid particular attention to those which would be important to patients and parents. For example, in considering abnormal hepatocellular enzymes, we examined normalization of abnormal hepatocellular enzymes, although our approach dichotomized a continuous measure. This was because the degree of abnormality of hepatocellular enzymes was not likely to be as important to a CF patient as the knowledge that the serum values of their enzymes were normal. There is also no evidence of a clear correlation between the serum level of hepatocellular enzymes and the degree of liver disease.
An important issue for patients with CF is the effect of UDCA on long-term outcome measures particularly the development of portal hypertension or its complications, the need for liver transplantation or mortality. However, these were not specifically addressed in these RCTs although we have been able to obtain some data from the six-month studies.
We are aware of only one ongoing RCT which is being undertaken at The Children's Hospital, Birmingham, UK (Spray C; personal communication). This study is a randomized, double-blind crossover study with treatment and control periods each lasting one year. Over the last five years, 21 patients have been recruited.
The UK Medical Research Council and other funding bodies now request details of a systematic review of existing RCTs prior to submission of a grant application for funding a RCT. The results of this systematic review indicate that there is an urgent need for a well-designed, adequately powered, multicentre RCT assessing the effectiveness of UDCA by measuring clinically relevant endpoints over years rather than months. We would suggest that these trials should assess the use of UDCA in the prevention as well as treatment of CF liver disease. Although we have not been able to perform a formal meta-analysis, the RCTs we have identified show important preliminary results. We recommend that because the evidence for its effectiveness is as yet inconclusive, UDCA should only be used in CF patients in the context of an RCT. 23 
